StockData
Virax Biolabs Group Ltd logo

Virax Biolabs Group Ltd (VRAX) stock

VRAXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends March 31
Financials through fiscal 2026, year ended Mar 31, 2026Last filing: 20-F on Jul 6, 2026Score 9/30
$0.33−0.05 (-12.89%)

Close on Nov 20, 2026Market cap $192.24KP/E –Yield –

Virax Biolabs gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

For fiscal 2026 it was $7.69K. The highest annual figure on record is $50.59K in fiscal 2024.

Annual gross profit

PeriodPeriod endValueChange
FY2026Mar 31, 2026$7.69K–
FY2025Mar 31, 2025-$53.07K-204.9%
FY2024Mar 31, 2024$50.59K–
FY2023Mar 31, 2023-$1.37K–
FY2021Mar 31, 2021-$9.43K–

More Virax Biolabs figures

See a number that looks wrong?